AR045659A1 - Derivados de tiazolopiridina - Google Patents
Derivados de tiazolopiridinaInfo
- Publication number
- AR045659A1 AR045659A1 ARP040103313A ARP040103313A AR045659A1 AR 045659 A1 AR045659 A1 AR 045659A1 AR P040103313 A ARP040103313 A AR P040103313A AR P040103313 A ARP040103313 A AR P040103313A AR 045659 A1 AR045659 A1 AR 045659A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- disease
- compounds
- heterocyclyl
- optionally substituted
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 230000004112 neuroprotection Effects 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- -1 tetrahydropyran-4-yl Chemical group 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 abstract 1
- KVYOWXUQJLOCIA-UHFFFAOYSA-N 1-oxa-8-azaspiro[4.5]decane Chemical compound C1CCOC21CCNCC2 KVYOWXUQJLOCIA-UHFFFAOYSA-N 0.000 abstract 1
- JTWGSQNWXVCXLD-UHFFFAOYSA-N 2-methyl-2,8-diazaspiro[4.5]decan-1-one Chemical compound O=C1N(C)CCC11CCNCC1 JTWGSQNWXVCXLD-UHFFFAOYSA-N 0.000 abstract 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos de la fórmula general (1), en la que: R1 es morfolin-4-ilo, fenilo o tetrahidropiran-4-ilo; R2 es -(CH2)n-arilo, sin sustituir o sustituido por uno o varios sustituyentes, elegidos entre el grupo formado por halógeno, alcoxi inferior, alquilo inferior, -(CH2)nNR'R'', -O(CH2)n-O-alquilo inferior y -(CH2)n-heterociclilo, o es heteroarilo, sin sustituir o sustituido por uno o varios sustituyentes, elegidos entre el grupo formado por alquilo inferior, alcoxi inferior, -(CH2)nNR'R'', - (CH2)n-heterociclilo, que está opcionalmente sustituido por hidroxi o alcoxi inferior, o es -(CH2)n-heterociclilo, opcionalmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por -(CH2)n-OH, -(CH2)n-O-alquilo inferior y alquilo inferior, o es -(CH2)n-cicloalquilo, o es -(CH2)n-O-alquilo inferior, o es NR'R'', o es benzo[1,3]dioxol, 2-metil-1-oxo-2,8-diaza-espiro[4,5]-decano, 2-oxa-5-aza-biciclo[2.2.1]heptano o 1-oxa-8-aza-espiro[4.5]decano; R', R'' con independencia entre sí con alquilo inferior, -(CH2)n-O-alquilo inferior o cicloalquilo, opcionalmente sustituido por hidroxi; n es 0, 1 ó 2; y a sales de adición de ácido farmacéuticamente aceptables de los mismos. Proceso de obtención de los compuestos de fórmula (1). Estos compuestos pueden utilizarse en el control o prevención de enfermedades basadas en la modulación del sistema de adenosina, por ejemplo la enfermedad de Alzheimer, la enfermedad de Parkinson, la enfermedad de Huntington, la neuroprotección, la esquizofrenia, la ansiedad, el dolor, los déficits de respiración, la depresión, la adición a las drogas, por ejemplo a la anfetaminas, la cocaína, los opiáceos, el etanol, la nicotina, los cannabinoides, o contra el asma, las reacciones alérgicas, la hipoxia, la isquemia, el ataque epiléptico y el abuso de sustancias. Los compuestos pueden ser útiles además como agentes sedantes, relajantes musculares, antipsicóticos, antiepilépticos, anticonvulsivos y cardioprotectores contra trastornos tales como la enfermedad de la arteria coronaria y el fallo cardíaco. Las indicaciones más preferidas son aquellas en las que incluyen trastornos del sistema nerviosos central, por ejemplo el tratamiento o la prevención de la enfermedad de Alzheimer, ciertos trastornos depresivos, la adicción a las drogas, la neuroprotección y la enfermedad de Parkinson así como el trastorno ADHD.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03021119 | 2003-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045659A1 true AR045659A1 (es) | 2005-11-02 |
Family
ID=34306777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103313A AR045659A1 (es) | 2003-09-19 | 2004-09-16 | Derivados de tiazolopiridina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7273865B2 (es) |
| EP (1) | EP1670805A1 (es) |
| JP (1) | JP2007505851A (es) |
| KR (1) | KR20060058132A (es) |
| CN (1) | CN1871244A (es) |
| AR (1) | AR045659A1 (es) |
| AU (1) | AU2004274154A1 (es) |
| BR (1) | BRPI0414266A (es) |
| CA (1) | CA2539314A1 (es) |
| MX (1) | MXPA06002943A (es) |
| RU (1) | RU2006112847A (es) |
| TW (1) | TWI297339B (es) |
| WO (1) | WO2005028484A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| EP1578422B1 (en) | 2002-12-20 | 2007-04-11 | NicoNovum AB | A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material |
| US20090163476A1 (en) * | 2005-03-03 | 2009-06-25 | Sirtris Pharmaceuticals, Inc. | N-Phenyl Benzamide Derivatives as Sirtuin Modulators |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7345178B2 (en) * | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007101270A1 (en) * | 2006-03-02 | 2007-09-07 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| JP2009535420A (ja) * | 2006-05-01 | 2009-10-01 | インサイト・コーポレイション | １１−βヒドロキシルステロイドデヒドロゲナーゼタイプ１のモジュレーターとしてのテトラ置換ウレア |
| KR101077295B1 (ko) * | 2006-05-18 | 2011-10-26 | 에프. 호프만-라 로슈 아게 | 아데노신 ａ2ｂ 수용체 길항물질로서의 티아졸로-피라미딘/피리딘 우레아 유도체 |
| FR2913886B1 (fr) | 2007-03-22 | 2012-03-02 | Guerbet Sa | Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| EP2215066A1 (en) * | 2007-11-01 | 2010-08-11 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| JP2011503066A (ja) * | 2007-11-08 | 2011-01-27 | サートリス ファーマシューティカルズ， インコーポレイテッド | 可溶化チアゾロピリジン誘導体 |
| CN102388054B (zh) | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| AU2014347027A1 (en) | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
| JP2017500287A (ja) * | 2013-11-06 | 2017-01-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体 |
| WO2015091584A1 (en) * | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors |
| CN103720703A (zh) * | 2013-12-24 | 2014-04-16 | 新乡医学院第一附属医院 | 腺苷a2a受体特异性阻断剂对延髓呼吸中枢的作用 |
| IT201600070952A1 (it) * | 2016-07-07 | 2018-01-07 | Univ Degli Studi Di Ferrara | NUOVI TIAZOLO[5,4-d]PIRIMIDIN DERIVATI QUALI AGONISTI INVERSI DEI RECETTORI A2A DELL’ADENOSINA |
| WO2019025099A1 (en) * | 2017-08-01 | 2019-02-07 | Merck Patent Gmbh | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS |
| KR20200043434A (ko) | 2017-08-21 | 2020-04-27 | 메르크 파텐트 게엠베하 | 아데노신 수용체 길항제로서의 퀴녹살린 유도체 |
| KR20200043433A (ko) | 2017-08-21 | 2020-04-27 | 메르크 파텐트 게엠베하 | 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체 |
| KR20210083287A (ko) | 2018-10-25 | 2021-07-06 | 메르크 파텐트 게엠베하 | 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체 |
| EP3870294A1 (en) | 2018-10-25 | 2021-09-01 | Merck Patent GmbH | 5-azaindazole derivatives as adenosine receptor antagonists |
| CN111205244B (zh) * | 2018-11-22 | 2023-08-18 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
| AR117844A1 (es) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2251419C2 (ru) * | 2000-06-21 | 2005-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензотиазола |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US6624163B2 (en) * | 2001-11-29 | 2003-09-23 | Hoffman-La Roche Inc. | Benzothiazole derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| US6734179B2 (en) * | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
| EP1456196B1 (en) * | 2001-12-12 | 2009-01-07 | F. Hoffmann-La Roche Ag | Benzothiophenes as adenosine receptor modulators |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
-
2004
- 2004-09-11 WO PCT/EP2004/010179 patent/WO2005028484A1/en not_active Ceased
- 2004-09-11 CN CNA2004800309594A patent/CN1871244A/zh active Pending
- 2004-09-11 MX MXPA06002943A patent/MXPA06002943A/es not_active Application Discontinuation
- 2004-09-11 JP JP2006526568A patent/JP2007505851A/ja active Pending
- 2004-09-11 EP EP04765102A patent/EP1670805A1/en not_active Ceased
- 2004-09-11 BR BRPI0414266-7A patent/BRPI0414266A/pt not_active IP Right Cessation
- 2004-09-11 KR KR1020067005454A patent/KR20060058132A/ko not_active Ceased
- 2004-09-11 CA CA002539314A patent/CA2539314A1/en not_active Abandoned
- 2004-09-11 AU AU2004274154A patent/AU2004274154A1/en not_active Abandoned
- 2004-09-11 RU RU2006112847/04A patent/RU2006112847A/ru not_active Application Discontinuation
- 2004-09-15 US US10/941,708 patent/US7273865B2/en not_active Expired - Fee Related
- 2004-09-16 TW TW093128066A patent/TWI297339B/zh not_active IP Right Cessation
- 2004-09-16 AR ARP040103313A patent/AR045659A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US7273865B2 (en) | 2007-09-25 |
| TWI297339B (en) | 2008-06-01 |
| CN1871244A (zh) | 2006-11-29 |
| AU2004274154A1 (en) | 2005-03-31 |
| BRPI0414266A (pt) | 2006-11-07 |
| MXPA06002943A (es) | 2006-05-31 |
| EP1670805A1 (en) | 2006-06-21 |
| JP2007505851A (ja) | 2007-03-15 |
| CA2539314A1 (en) | 2005-03-31 |
| US20050065151A1 (en) | 2005-03-24 |
| KR20060058132A (ko) | 2006-05-29 |
| WO2005028484A1 (en) | 2005-03-31 |
| TW200526670A (en) | 2005-08-16 |
| RU2006112847A (ru) | 2007-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schneider et al. | Dopamine autoreceptor agonists: resolution and pharmacological activity of 2, 6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine | |
| AU2010298166B2 (en) | Pyrido[4,3-b]indoles and methods of use | |
| US9034869B2 (en) | Bridged heterocyclic compounds and methods of use | |
| JP5791612B2 (ja) | ピリド［３，４−ｂ］インドールおよび使用方法 | |
| AU2010282990B2 (en) | Pyrido [4, 3-b] indoles and methods of use | |
| JP5791611B2 (ja) | ピリド［３，４−ｂ］インドールおよび使用方法 | |
| AU2010242910B2 (en) | Pyrido [4,3-b] indoles and methods of use | |
| BRPI0414266A (pt) | derivados de tiazolopiridina como ligandos receptores da adenosina | |
| MX2007012637A (es) | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos. | |
| EP2480081A1 (en) | Bridged heterocyclic compounds and methods of use | |
| WO2011014695A1 (en) | New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use | |
| JP2020520925A (ja) | 化合物、組成物および方法 | |
| RU2469033C2 (ru) | СОЕДИНЕНИЯ ДИБЕНЗО[b,f][1,4]ОКСАЗАПИНА | |
| KR20100039331A (ko) | 치료용 피라졸로퀴놀린 유도체 | |
| Morice et al. | Ring transformations | |
| TH78440A (th) | อนุพันธุ์ไธอะโซโลไพริดีน | |
| HK1157751B (en) | Bridged heterocyclic compounds and methods of use | |
| AU2013203574A1 (en) | Pyrido [4,3-b] indoles and methods of use | |
| HK1154490B (en) | 2,3,4,5-terahydro-1h-pyrido [4,3-b] indole compounds and methods of use thereof | |
| HK1154490A1 (en) | 2,3,4,5-terahydro-1h-pyrido [4,3-b] indole compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |